Literature DB >> 19237575

The role of the CD58 locus in multiple sclerosis.

Philip L De Jager1, Clare Baecher-Allan, Lisa M Maier, Ariel T Arthur, Linda Ottoboni, Lisa Barcellos, Jacob L McCauley, Stephen Sawcer, An Goris, Janna Saarela, Roman Yelensky, Alkes Price, Virpi Leppa, Nick Patterson, Paul I W de Bakker, Dong Tran, Cristin Aubin, Susan Pobywajlo, Elizabeth Rossin, Xinli Hu, Charles W Ashley, Edwin Choy, John D Rioux, Margaret A Pericak-Vance, Adrian Ivinson, David R Booth, Graeme J Stewart, Aarno Palotie, Leena Peltonen, Bénédicte Dubois, Jonathan L Haines, Howard L Weiner, Alastair Compston, Stephen L Hauser, Mark J Daly, David Reich, Jorge R Oksenberg, David A Hafler.   

Abstract

Multiple sclerosis (MS) is an inflammatory disease of the central nervous system associated with demyelination and axonal loss. A whole genome association scan suggested that allelic variants in the CD58 gene region, encoding the costimulatory molecule LFA-3, are associated with risk of developing MS. We now report additional genetic evidence, as well as resequencing and fine mapping of the CD58 locus in patients with MS and control subjects. These efforts identify a CD58 variant that provides further evidence of association with MS (P = 1.1 x 10(-6), OR 0.82) and the single protective effect within the CD58 locus is captured by the rs2300747(G) allele. This protective rs2300747(G) allele is associated with a dose-dependent increase in CD58 mRNA expression in lymphoblastic cell lines (P = 1.1 x 10(-10)) and in peripheral blood mononuclear cells from MS subjects (P = 0.0037). This protective effect of enhanced CD58 expression on circulating mononuclear cells in patients with MS is supported by finding that CD58 mRNA expression is higher in MS subjects during clinical remission. Functional investigations suggest a potential mechanism whereby increases in CD58 expression, mediated by the protective allele, up-regulate the expression of transcription factor FoxP3 through engagement of the CD58 receptor, CD2, leading to the enhanced function of CD4(+)CD25(high) regulatory T cells that are defective in subjects with MS.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19237575      PMCID: PMC2664005          DOI: 10.1073/pnas.0813310106

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  32 in total

1.  Haploview: analysis and visualization of LD and haplotype maps.

Authors:  J C Barrett; B Fry; J Maller; M J Daly
Journal:  Bioinformatics       Date:  2004-08-05       Impact factor: 6.937

2.  A haplotype map of the human genome.

Authors: 
Journal:  Nature       Date:  2005-10-27       Impact factor: 49.962

3.  Induction of CD4+CD25+ regulatory T cells by copolymer-I through activation of transcription factor Foxp3.

Authors:  Jian Hong; Ningli Li; Xuejun Zhang; Biao Zheng; Jingwu Z Zhang
Journal:  Proc Natl Acad Sci U S A       Date:  2005-04-25       Impact factor: 11.205

4.  MHC class II expression identifies functionally distinct human regulatory T cells.

Authors:  Clare Baecher-Allan; Elizabeth Wolf; David A Hafler
Journal:  J Immunol       Date:  2006-04-15       Impact factor: 5.422

Review 5.  The TDT and other family-based tests for linkage disequilibrium and association.

Authors:  R S Spielman; W J Ewens
Journal:  Am J Hum Genet       Date:  1996-11       Impact factor: 11.025

6.  Decreased FOXP3 levels in multiple sclerosis patients.

Authors:  Jianya Huan; Nicole Culbertson; Leslie Spencer; Richard Bartholomew; Gregory G Burrows; Yuan K Chou; Dennis Bourdette; Steven F Ziegler; Halina Offner; Arthur A Vandenbark
Journal:  J Neurosci Res       Date:  2005-07-01       Impact factor: 4.164

Review 7.  Multiple sclerosis.

Authors:  David A Hafler
Journal:  J Clin Invest       Date:  2004-03       Impact factor: 14.808

8.  The role of 2 FOXP3 isoforms in the generation of human CD4+ Tregs.

Authors:  Sarah E Allan; Laura Passerini; Rosa Bacchetta; Natasha Crellin; Minyue Dai; Paul C Orban; Steven F Ziegler; Maria Grazia Roncarolo; Megan K Levings
Journal:  J Clin Invest       Date:  2005-10-06       Impact factor: 14.808

9.  A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis.

Authors:  Chris H Polman; Paul W O'Connor; Eva Havrdova; Michael Hutchinson; Ludwig Kappos; David H Miller; J Theodore Phillips; Fred D Lublin; Gavin Giovannoni; Andrzej Wajgt; Martin Toal; Frances Lynn; Michael A Panzara; Alfred W Sandrock
Journal:  N Engl J Med       Date:  2006-03-02       Impact factor: 91.245

10.  Loss of functional suppression by CD4+CD25+ regulatory T cells in patients with multiple sclerosis.

Authors:  Vissia Viglietta; Clare Baecher-Allan; Howard L Weiner; David A Hafler
Journal:  J Exp Med       Date:  2004-04-05       Impact factor: 14.307

View more
  76 in total

Review 1.  Multiple sclerosis.

Authors:  Alyssa Nylander; David A Hafler
Journal:  J Clin Invest       Date:  2012-04-02       Impact factor: 14.808

Review 2.  Multiple sclerosis genetics--is the glass half full, or half empty?

Authors:  Jorge R Oksenberg; Sergio E Baranzini
Journal:  Nat Rev Neurol       Date:  2010-07-13       Impact factor: 42.937

Review 3.  Genetic determinants of risk and progression in multiple sclerosis.

Authors:  Alessandro Didonna; Jorge R Oksenberg
Journal:  Clin Chim Acta       Date:  2015-02-04       Impact factor: 3.786

Review 4.  From genes to function: the next challenge to understanding multiple sclerosis.

Authors:  Lars Fugger; Manuel A Friese; John I Bell
Journal:  Nat Rev Immunol       Date:  2009-06       Impact factor: 53.106

5.  Differential expression, and genetic association, of CD58 in Swedish multiple sclerosis patients.

Authors:  Boel Brynedal; Izaura Lima Bomfim; Tomas Olsson; Kristina Duvefelt; Jan Hillert
Journal:  Proc Natl Acad Sci U S A       Date:  2009-06-02       Impact factor: 11.205

6.  Clinical relevance and functional consequences of the TNFRSF1A multiple sclerosis locus.

Authors:  Linda Ottoboni; Irene Y Frohlich; Michelle Lee; Brian C Healy; Brendan T Keenan; Zongqi Xia; Tanuja Chitnis; Charles R Guttmann; Samia J Khoury; Howard L Weiner; David A Hafler; Philip L De Jager
Journal:  Neurology       Date:  2013-10-30       Impact factor: 9.910

7.  Genome-wide association study in a high-risk isolate for multiple sclerosis reveals associated variants in STAT3 gene.

Authors:  Eveliina Jakkula; Virpi Leppä; Anna-Maija Sulonen; Teppo Varilo; Suvi Kallio; Anu Kemppinen; Shaun Purcell; Keijo Koivisto; Pentti Tienari; Marja-Liisa Sumelahti; Irina Elovaara; Tuula Pirttilä; Mauri Reunanen; Arpo Aromaa; Annette Bang Oturai; Helle Bach Søndergaard; Hanne F Harbo; Inger-Lise Mero; Stacey B Gabriel; Daniel B Mirel; Stephen L Hauser; Ludwig Kappos; Chris Polman; Philip L De Jager; David A Hafler; Mark J Daly; Aarno Palotie; Janna Saarela; Leena Peltonen
Journal:  Am J Hum Genet       Date:  2010-02-12       Impact factor: 11.025

Review 8.  The plasticity of human Treg and Th17 cells and its role in autoimmunity.

Authors:  Markus Kleinewietfeld; David A Hafler
Journal:  Semin Immunol       Date:  2013-11-05       Impact factor: 11.130

Review 9.  T-cell exhaustion: understanding the interface of chronic viral and autoinflammatory diseases.

Authors:  Eoin F McKinney; Kenneth Gc Smith
Journal:  Immunol Cell Biol       Date:  2016-11       Impact factor: 5.126

10.  GWASs and the age of human as the model organism for autoimmune genetic research.

Authors:  Robert Plenge
Journal:  Genome Biol       Date:  2010-05-05       Impact factor: 13.583

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.